Mark Lappe, New Inhibrx CEO

Sanofi wades in­to AATD in $1.7B bid for In­hi­brx's rare dis­ease drug

In its first M&A move of 2024, Sanofi is grab­bing what it sees as a po­ten­tial best-in-class ther­a­py for its rare dis­ease pipeline by snap­ping up In­hi­brx in a $1.7 bil­lion deal.

While Sanofi is nom­i­nal­ly ac­quir­ing the whole of In­hi­brx, it will on­ly keep the lead drug — a Phase II hu­man re­com­bi­nant pro­tein de­signed to treat al­pha-1 an­tit­rypsin de­fi­cien­cy, or AATD — while all the oth­er pro­grams get spun out in­to a sep­a­rate com­pa­ny called New In­hi­brx. The French drug­mak­er will al­so re­tain an 8% eq­ui­ty stake in New In­hi­brx.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.